AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
First Trust Advisors LP grew its holdings in AptarGroup, Inc. (NYSE: ATR) by 42.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 538,554 shares of the industrial products company's stock after acquiring an additional 160,763 shares during the period.
AptarGroup (ATR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announces the first commercial launch of its innovative auto-loading, dosing dropper technology called NeoDropper Autoload. Aptar's technology is featured on Dermalogica's FutureCode Booster skincare product. Designed for prestige skincare and dermocosmetic brands, this next-generation dropper packaging is intended to address consumer needs around dosage control, convenience and clean usage by supporting precision dispensing and user experience.
Chicago Partners Investment Group LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,051 shares of the industrial products company's stock, valued at approximately $505,000. A number of other
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026.
First Trust Advisors LP grew its holdings in AptarGroup, Inc. (NYSE: ATR) by 42.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 538,554 shares of the industrial products company's stock after acquiring an additional 160,763 shares during the period.
AptarGroup (ATR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announces the first commercial launch of its innovative auto-loading, dosing dropper technology called NeoDropper Autoload. Aptar's technology is featured on Dermalogica's FutureCode Booster skincare product. Designed for prestige skincare and dermocosmetic brands, this next-generation dropper packaging is intended to address consumer needs around dosage control, convenience and clean usage by supporting precision dispensing and user experience.
Chicago Partners Investment Group LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,051 shares of the industrial products company's stock, valued at approximately $505,000. A number of other
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026.
AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
-- ATR 1072 is the company's first precision cardiology program to enter the clinic -- -- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease -- SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. "PRKAG2 syndrome and other rare genetic cardiomyopathies represent a profound unmet need — these are progressive, life-altering and life-threatening diseases that often strike early, affect multiple members of the same family, and have no approved therapy to address their root cause," said Kathleen Gallagher, President and Chief Executive Officer, Atrium Therapeutics.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Releases 2025 Corporate Sustainability Report.
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
On June 09, 2026, AptarGroup Inc (ATR) shares rose 3.5% today, currently priced at $115.90. The stock has experienced a 52-week range of $103.23 to $164.28, ref
AptarGroup, Inc. (ATR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences.
AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
ITAD Firm, Advanced Technology Recycling (ATR), now offers wholesale electronics and computers to the general public through our online auction platform.
On May 01, 2026, AptarGroup Inc (ATR) shares fell 3.8% to a current price of $119.02. The stock has experienced significant volatility over the past year, with
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
AptarGroup (ATR) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.2 per share a year ago.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports First Quarter 2026 Results.
AVY beats Q1 earnings estimates on strong volumes and cost control, with profits rising and cash flow swinging to positive despite mixed segment performance.
Graphic Packaging (GPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avery Dennison (AVY) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.41 per share. This compares to earnings of $2.3 per share a year ago.
Cwm LLC increased its position in shares of AptarGroup, Inc. (NYSE: ATR) by 102.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,781 shares of the industrial products company's stock after purchasing an additional 5,457 shares during the quarter. Cwm
